Answers are grounded in this paper and cite their sources.
Dry eye disease (DED) is a prevalent ocular condition associated with systemic inflammation, and the gut–eye axis has emerged as a potential therapeutic target. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of LB-101, a probiotic complex comprising Lactiplantibacillus plantarum NK151 and Bifidobacterium bifidum NK175, in adults with DED. Eighty participants were randomized to LB-101 or placebo once daily for 8 weeks, of whom 62 participants completed the study and were included in the final efficacy analysis. After 8 weeks, the LB-101 group demonstrated a statistically significant improvement in tear break-up time compared to placebo (mean difference: 1.01 s, 95% CI 0.01–2.01, p = 0.047). Significant improvements were also observed in certain individual symptom-level Ocular Surface Disease Index (OSDI) items. However, total OSDI scores and most other objective ocular surface endpoints did not differ significantly between the groups. Exploratory gut microbiota analysis revealed a significant increase in Carnobacteriaceae and a decrease in the endotoxin-producing bacterial family Oxalobacteraceae in the LB-101 group. No serious adverse events occurred. In conclusion, oral administration of LB-101 for 8 weeks improved tear film stability and certain symptom-level OSDI items, although total OSDI and most objective endpoints remained nonsignificant, with exploratory microbiome findings supporting the therapeutic relevance of the gut–eye axis in DED.
No takes yet. Share an insight, caveat, or question.
Son et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: